Purinyl derivatives and their use as potassium channel modulators
This invention relates to novel purinyl derivatives of formula Ia or Ib Wherein the symbols are as defined in the Specification and of pharmaceutically acceptable salts thereof useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.
1. A purinyl derivative of Formula Ia or Ib
or a pharmaceutically acceptable salt thereof, wherein
n is 0;
X represents NH;
Y represents phenyl, optionally substituted with halo;
R 1 represents alkyl; and
Het represents a pyrazolyl group substituted two or more times with alkyl.
2. The purinyl derivative of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y represents phenyl substituted with halo.
3. The purinyl derivative of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 represents methyl.
4. The purinyl derivative according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein Het represents pyrazolyl which is substituted two times with alkyl.
5. The purinyl derivative of claim 1 , which is
(4-Chloro-phenyl)-[2-(3,5-dimethyl-pyrazol-1-yl)-9-methyl-9H-purin-6-yl]-amine;
(4-Chloro-phenyl)-[2-(3,5-dimethyl-pyrazol-1-yl)-7-methyl-7H-purin-6-yl]-amine;
(4-Chloro-phenyl)-[2-(3,5-dimethyl-pyrazol-1-yl)-9-ethyl-9H-purin-6-yl]-amine;
[2-(3,5-Dimethyl-pyrazol-1-yl)-9-methyl-9H-purin-6-yl]-(4-fluoro-phenyl)-amine;
(4-Chloro-phenyl)-[2-(3,5-dimethyl-pyrazol-1-yl)-9-isobutyl-9H-purin-6-yl]-amine;
[2-(3,5-Dimethyl-pyrazol-1-yl)-9-methyl-9H-purin-6-yl]-phenyl-amine;
(4-Bromo-phenyl)-[2-(3,5-dimethyl-pyrazol-1-yl)-9-methyl-9H-purin-6-yl]-amine;
(4-Chloro-phenyl)-[2-(3,5-diethyl-pyrazol-1-yl)-9-methyl-9H-purin-6-yl]-amine;
(4-Chloro-phenyl)-[9-methyl-2-(3,4,5-trimethyl-pyrazol-1-yl)-9H-purin-6-yl]-amine;
or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising a therapeutically-effective amount of a purinyl derivative according to claim 1 , or a pharmaceutically-acceptable addition salt thereof, or a prodrug thereof, together with at least one pharmaceutically-acceptable carrier or diluent.
7. The purinyl derivative of claim 1 , which is
(4-Chloro-phenyl)-[2-(3,5-dimethyl-pyrazol-1-yl)-9-methyl-9H-purin-6-yl]-amine; or a pharmaceutically acceptable salt thereof.